- Regeneus has announced positive results from its preclinical trial of Progenza
- Researchers gave injections using Progenza to a rat for 14 days and it reversed the allodynia in the animal
- The preclinical results showed significant potential for Progenza to be used in human trials
Regeneus has announced positive results from its preclinical trial of Progenza.
Progenza is a treatment for allodynia, a condition in which pain occurs from what is normally non-painful stimulation of the skin, such as light touch.
The trial was completed with the University of Adelaide by Professor Mark Hutchinson.
Results of the preclinical trial was studied on a rat, which allowed for the graded measurement of neuropathic pain to match human neuropathic pain conditions.
Researchers gave injections using Progenza to the rat for 14 days and it reversed the allodynia in the animal.
The preclinical results showed significant potential for Progenza in the treatment of neuropathic pain.
Mark believes it is uncommon to identify treatments that reverse pain like Progenza did.
“Progenza was capable of this long-term complete reversal of the exaggerated pain behaviour. This is the type of a treatment response that is highly desirable for a new therapy,” he said.
Regeneus is an Australian clinical-stage regenerative medicine company, focusing on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.
Non-Executive Director, Dr Alan Dunton is pleased with the results.
“Studies like this support the development of Progenza for treating neuropathic pain where very few options exist,” he said.
The new results supports the company’s growth strategy targeting the global neuropathic pain market, which currently has limited successful treatment options.
The global neuropathic pain industry is estimated to be worth US$69 billion and is expected to reach US$79 billion by 2024.
Shares have remained steady since yesterday trading for 10.5 cents with a market cap of $21.93 million.